Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LONG-PRAXOL: Long-term Efficacy of Add-on Pramipexole for Anhedonic Depression
NCT05825235Phase 3Completed
- Sponsor
- Region Skåne
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pramipexole in major depressive disorder (MDD) and anhedonia ((none)), sponsored by Region Skåne. Primary endpoint: Anhedonia symptoms at 6 months. Started Apr 2023; status: completed.
02
Drugs
pramipexole
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on NCT05825235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05825235.